The shares of this pharmaceutical company gained up to 6 percent after the company’s net profit and revenue increased by 119 percent and 13 percent QoQ, respectively in Q1FY25,
With a market capitalization of Rs 91,169.05 crore, the shares of Lupin Ltd were trading at Rs 1,999.25 per share, increasing around 5 percent as compared to the previous closing price of Rs 1,907.00 apiece.
Reason for rise:-
The share of the company has seen positive movement after Lupin Ltd’s revenue zoomed by 12 percent on a quarter-on-quarter basis from Rs. 4,961 crores in Q4FY24 to Rs.5,600 crores in Q1FY25. Further, revenue magnified by 16 percent yearly from Rs 4,814 crores in Q1FY24 to Rs. 5,600 crores in Q1FY25.
Lupin Ltd’s net profit increased by 119 percent on a quarter-on-quarter basis from Rs. 368 crores in Q4FY24 to Rs 806 in Q1FY25. Further, on a year-on-year basis also net profit magnified drastically by 78 percent from Rs. 453 crores in Q1FY24 to Rs. 806 crores in Q1FY25.
Also read
Geographical presence:-
The company offers branded and generic formulations, biotechnology products, and APIs in over 100 regions, including the US, India, South Africa, APAC, LATAM, Europe, and the Middle East.
The firm specializes in cardiovascular, anti-diabetic, and respiratory divisions, as well as anti-infective, GI, CNS, and women’s health products. Lupin is the third-largest pharmaceutical company in the US, according to prescriptions. In fiscal year 24, the company allocated 7.8% of its sales on research and development.
Manufacturing facilities:-
The firm operates 15 production locations, and 7 research centers, employs over 20,000 individuals worldwide and is frequently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals industry.
Company Snapshot:-
Lupin Limited produces, develops, and markets branded and generic formulations, biotechnology products, and APIs internationally. The company operates in several fields, including cardiology, diabetes, asthma, pediatrics, and central nervous system.
Written by:- Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
